Objectives: To identify potential molecular genetic determinants of cardiovascular ischemic tolerance in wild-type and transgenic hearts overexpressing A adenosine receptors (A ARs). Methods: cDNA microarrays were used to explore expression of 1824 genes in 
. Introduction
translational, involve protein expression elements [1] and may be sensitive to gene transcription. Investigators have Molecular mechanisms underlying cell death and commenced analysis of gene expression in ischemic hearts dysfunction following ischemia-reperfusion are undefined, [2] [3] [4] in the hope of identifying genes involved in genesis and molecular genetic determinants of ischemic tolerance of ischemic injury. Such investigations are essential if the poorly characterized. Research has focussed on post-transtherapeutic potential of 'gene therapy' is to be realized in lational modification of phenotype. However, pre-and ischemic tissue. Few if any studies have addressed the post-ischemic phenotypes will be determined by gene genetic basis of ischemia-tolerant phenotypes. expression prior to and following insult. Recent evidence
We recently characterized marked protection from isindicates acute responses, previously considered postchemia with cardiac A AR overexpression, leading to 1 reduced contractile dysfunction, de-energization, necrosis and infarction [5] [6] [7] [8] . Degree of protection exceeds that for other interventions, including preconditioning [8] . Molecu-(200 nM) initiated 10 min prior to ischemia. The agent lar mechanisms remain to be determined, but may involve was infused during and following ischemia since we K channels [7] , are common to preconditioning [8] , and previously identified protective functions of adenosine at ATP differ from those for A AR activation [9] . We have not these times [11] . Finally, A AR-mediated negative 3 1 ascertained whether tolerance involves transcriptional chronotropic responses to the non-selective agonist 2-changes prior to and following ischemia. The aims of the chloroadenosine were assessed as described previously present study were to identify effects of A AR overexpres- [12] in normoxic wild-type (n58) and transgenic hearts 1 sion and ischemia on myocardial gene expression. A (n58), and post-ischemic wild-type (n59) and transgenic cDNA microarray containing |2000 genes, or |10% of the hearts (n58) after 45 min reperfusion. cardiovascular genome [10] , was employed to assess expression in wild-type hearts and hearts overexpressing 2 .2. RNA isolation and DNA microarray analysis A ARs. Differential expression was verified by quantita-1 tive real-time PCR analysis in a subset of genes, and Ventricular myocardium was homogenized and total expression of the A AR gene was studied.
RNA extracted using standard TRIzol and DNase treat-1 ment with subsequent spin column purification (Qiagen, Hilden, Germany). Ventricular RNA from a subset of 2 . Methods hearts investigated (n58 for non-ischemic wild-types, n56 for all other groups) was pooled per group to reduce 2 .1. Langendorff model inter-experiment and inter-animal variability. Preparation of differentially labeled fluorescent cDNA, Investigations conformed with the Guide for the Care hybridization and washing of microarray slides were and Use of Laboratory Animals published by the US performed as described previously [13] . Microarrays conNational Institutes of Health (NIH Publication No. 85-23, sisted of 1632 sequence verified cDNAs from the Research revised 1996). Hearts were obtained from mature 20-28- Genetics mouse UniGene set, 192 other known genes week-old male and female wild-type mice (n544, (primarily involved in development and differentiation) 29.163.6 g body weight, 13367 mg wet heart weight) and and positive and negative controls, all immobilized in transgenic mice overexpressing cardiac A AR (n541, duplicate on glass slides. Each hybridization was repeated 1 27.862.4 g body weight, 12668 mg wet heart weight) with experimental and control samples reciprocally anesthetized with 50 mg / kg sodium pentobarbital adminislabeled. tered intraperitoneally. Details regarding generation and characterization of transgenic mice have been published 2 .3. Digital image analysis and data processing previously [5, 7, 8] . Hearts were removed and perfused in a Langendorff mode as described in detail previously [6, 7, 9] .
Scanning of arrays was performed using a GMS 418 After 20 min stabilization hearts were switched to scanner (Affymetrix, Santa Clara, CA), image analysis was pacing at 400 beats / min [5] [6] [7] [8] [9] . After a further 10 min performed using ImaGene 4.1 (BioDiscovery, Los baseline measurements were made and hearts subjected to Angeles, CA). Briefly, this involved spot segmentation, 30 min global ischemia and 60 min reperfusion or 90 min gridding and flagging of poor and empty spots (exclusion aerobic perfusion (non-ischemic controls). This was perof spots with signal:noise ratio ,3, spots ,40% of average formed in wild-type (n59 ischemia-reperfusion, n59 nonarea, irregular spots). GeneSight-Lite (BioDiscovery, Los ischemic) and transgenic hearts overexpressing A AR (n5 Angeles, CA) was used for local background subtraction 1 8 ischemia-reperfusion, n59 non-ischemic). Function was and global normalization of fluorescent intensities before monitored throughout, and coronary effluent throughout exporting as a spreadsheet. Since $2 replicates are essenreperfusion collected for purine analysis by HPLC [11] and tial in any microarray study [14] experiments were relactate dehydrogenase analysis using a commercial specpeated on 2-3 replicate slides for each group, with each trophotometric assay kit (Sigma Chemicals, St. Louis, MO, slide containing duplicate spots for every gene. The cDNA USA) [8, 9] . Ectopy during the initial 10 min reperfusion labeling with Cy3 and Cy5 was reversed on one slide from was assessed: total number of abnormal or premature beats each group and expression patterns compared to validate were determined and ectopy calculated as: %Ectopy5 consistency of expression profiles and eliminate possible abnormal beats / total beats3100%. Time for hearts to non-uniform labeling. commence beating following ischemia was also determined. On completion of experiments hearts were freeze-2 .4. Quantitative real-time PCR clamped in aluminium tongs cooled in liquid N and stored 2 at 280 8C until RNA extraction.
Differential expression was confirmed in nine transcripts To assess the role of A AR activation, wild-type (n59) via real-time PCR using an iCycler iQ real-time PCR 1 and transgenic hearts (n58) were subjected to ischemiadetection system (Bio-Rad Laboratories, Hercules, CA). reperfusion with infusion of the A AR antagonist DPCPX We selected nine genes identified in arrays as being 1 unchanged, induced or down-regulated in one or more shown). Diastolic pressure remained elevated after reperfuexperimental groups studied (providing a broad range of sion at |20 mmHg in wild-type hearts but recovered to expression to validate with real-time PCR): Pdha1, Idh3a, control in transgenic hearts (Fig. 1A) . Ventricular deDdit3, Rgs5, Hspe1, Ywhag, Atp5F1, Fhl2 and Csf1.
veloped pressure, 1 dP/dt and 2 dP/ dt all remained Additionally we investigated expression of the A AR gene depressed by |50% in wild-type hearts (Fig. 1 Table 1 . Function was similar in ischemia-reperfusion in wild-type hearts, and 67 in transwild-type and transgenic hearts, although intrinsic heart genic hearts (Table 2) . We grouped genes into those rate was reduced with A AR overexpression. Ischemia encoding proteins involved in: (i) energy / metabolism; (ii) 1 abolished contractile function in wild-type and transgenic structure / motility (matrix, cytoskeletal, contractile, microhearts, as documented previously [5] [6] [7] [8] [9] . Diastolic contractubule); (iii) cell signaling (receptors, effectors, intracelluture was rapid, with time to contracture (rise in diastolic lar transducers, protein modifiers); (iv) cell defence / pressure of 20 mmHg) shorter in wild-types (258614 s) growth (stress response, apoptotic, DNA synthesis / repair, vs. transgenics (397617 s) (P,0.05). Peak contracture immune / inflammatory); (v) gene expression (RNA synpressure during ischemia was not different (8467 mmHg thesis, transcription factors, chromatin-related); (vi) in wild-types, 8968 mmHg in transgenics). Coronary flow modifying protein synthesis (processing, turnover, postrecovered to similar levels in both groups, and did not translational modification, trafficking, ribosomal); and (vii) differ significantly from non-ischemic hearts (data not unclassified functions. ( Fig. 2 , Table 2 ). However, the general pattern was quite different in the groups-less were induced vs. downregulated in wild-type hearts whereas the reverse occurred in transgenics (Fig. 2) . Of genes modified, 24 were common to wild-types and transgenic hearts (indicated in Table 2 ). Thus, 43 genes were modified in transgenic but not wild-type hearts.
.4. Cellular metabolism genes
Repression of metabolic genes was characteristic of post-ischemic wild-type hearts ( Table 2 ). Enzymes of carbohydrate metabolism (e.g. pyruvate dehydrogenase, isocitrate dehydrogenase, GAPDH), fatty acid metabolism (e.g. malonyl-CoA-decarboxylase, dodecenoyl-coenzyme A delta isomerase), and mitochondrial oxidative phosphorylation (adenine nucleotide translocase, mitochondrial ATP synthase) were repressed post-ischemia. PEP carboxykinase 1 and adenylosuccinate lyase were induced in wild-types (Table 2) . A AR overexpression completely or 1 partially reversed repression of metabolic genes ( Table 2 , Fig. 3A ), selectively reduced mitochondrial-uncoupling protein 2, and induced glycogen phosphorylase, Slc3a2, and NADH dehydrogenase (ubiquinone) ( Table 2 ).
.5. Structural /motility genes
Structural, cytoskeletal and myofibrillar genes was altered by ischemia. b-actin, cadherin-2, b-catenin, tropomodulin 2, a-tubulin 4, and ankyrin-1 were all downregulated ( Table 2) . Only elastin was significantly induced in wild-types. These changes, excluding down-regulation of b-catenin, were reversed by A AR overexpression. regulated by ischemia in wild-type and transgenic hearts. Heat shock proteins Hsp84, Hsp47 and chaperonin 10 Transcriptional patterns for post-ischemic hearts are (Hspe1) were induced by ischemia-reperfusion in both depicted in Fig. 2 . Similar total numbers of transcripts groups. Induction of DNA-damage inducible transcript 3 were altered in wild-type (75) and transgenic (67) hearts (Ddit3 or Gadd153 / Chop-10) was also observed in both (Table 2 ). There was a general trend of post-ischemic gene induction in transgenic 4 . Discussion hearts compared to down-regulation in wild-type hearts (Table 2) . Deoxyhypusine synthase was the only gene Identifying transcriptional patterns conferring resistance induced by ischemia in both groups.
.7. Cell defence and growth-related genes
(or sensitivity) to ischemic insult is an important step in understanding ischemic and reperfusion injures, and in 3 .9. Quantitative real-time PCR analysis and A AR developing genetic approaches to ischemic disorders. As 1 function indicated in the recent review by Henriksen and Kotelevtsev, although it is not technically feasible to simultaneousReal-time PCR confirmed differential expression of ly profile expression of large numbers of proteins it is Pdha1, Idh3a, Atp5F1, Csf1, Rgs5, Ywhag, Hspe1, Ddit3 possible to profile transcription of large numbers of genes and Fhl2 (Fig. 3) . Expression data from the alternate [16] . This facilitates identification of potential proteins and methodologies were comparable (Fig. 4) . Expression of pathways involved in generating particular phenotypes. In A AR gene (Adora1) was predictably higher in transgenic the current study we identify changes in expression of 1 vs. wild-type hearts. Interestingly, Adora1 was induced by novel and characterized genes in ischemia-tolerant hearts, ischemia-reperfusion in transgenic hearts but down-regand also observe a number of novel gene changes associulated in wild-types (Fig. 5) . This pattern was consistent ated with ischemic insult.
receptor kinase, insulin-like growth factor binding protein, regulator of G-protein signaling), and it is tempting to speculate enhanced activation of G-coupled A AR leads to 1 modulation of proteins involved in G-protein signaling. One novel observation is down-regulation of mitochondrial uncoupling protein 2, which is an inhibitor of myocardial efficiency [17] . We have previously shown adenosine enhances efficiency of O use in myocardium [18] . Since 2 the protected phenotype is sensitive to A AR antagonism, 1 the importance of these varied gene changes in ischemictolerance is questionable.
.2. Gene expression in ischemic-reperfused myocardium
There is evidence acute myocardial responses, thought to be post-translational in nature (e.g. preconditioning), may involve translational or transcriptional components [1] . Moreover, there is indirect evidence adenosine modifies myocardial gene expression [19, 20] . Microarrays are powerful tools in identifying transcriptional effects of ischemia and modification by A AR overexpression. The 1 approach has been employed in post-ischemic [3, 4] , cardiomyopathic [21] , hypertrophic [22] , and failing hearts [23] . Of the almost 1000 arrayed genes expressed, 75 were consistently modified by ischemia-reperfusion in wild-type myocardium. The major proportion (|80%) are repressed as opposed to induced ( Table 2, Fig. 2 ). The post-ischemic profile involves down-regulation of cellular metabolic 
non-ischemic tissue
While data regarding gene expression is insufficient to confirm functional relationships between and roles for Consistent with previous data [7, 8] , A AR overexpresdifferent proteins, transcriptional profiling provides clues 1 sion generates an ischemia-tolerant phenotype characterto mechanisms contributing to ischemic tolerance, injury ized by improved functional recovery and impaired necroand remodeling, and permits development of testable sis (Fig. 1) . Additionally, we show arrhythmogenesis is hypotheses. For example, a 'cluster' of glycolytic genes reduced. While data support roles for mitochondrial K were down-regulated, including pyruvate dehydrogenase, ATP channel activation [7] and energy metabolism [6] , molecu-GAPDH, isocitrate dehydrogenase, and aldolase. These lar determinants of ischemia tolerance are poorly defined.
changes are predicted to reduce flux through glycolysis, The ischemia-tolerant phenotype is sensitive to A AR consistent with impaired post-ischemic glucose oxidation sion could contribute to dysfunction. Greatest changes were observed for b-catenin (cell adhesion), peroxisomal farnesylated protein (peroxisomal biogenesis), cadherin 2 (intercalated disc protein), a-tubulin (cytoskeletal protein), and b-actin. The majority of changes were abolished with A AR overexpression (Table 2) , consistent with roles in 1 the post-ischemic phenotype. A small number of genes involved in cell signaling were altered by ischemia, and some were selectively modified by A AR overexpression. Ischemia down-regulated protein 1 phosphatase-2 subunits and PCTAIRE protein kinase 1, and induced DNA-activated protein kinase. Since contractility and myocardial apoptosis are sensitive to protein phosphorylation, modification of phosphatases and kinases could have important effects in post-ischemic tissue (which is characterized by enhanced apoptosis and contractile dysfunction). relative to wild-type non-ischemic hearts (n58) for the purposes of comparing real-time PCR data with microarray data.
Induction of Hspe1 and Egr1 in transgenic hearts is consistent with cardioprotection since Hspe1 protects lism. Importantly, A AR overexpression reversed the against ischemia [29] , and Egr1 is up-regulated after 1 majority of changes in metabolic genes, and induced injury, inducing growth related genes [30] . The glycoproseveral including phosphoenolpyruvate carboxykinase 1 tein clusterin (or apolipoprotein J) also inhibits apoptosis and glycogen phosphorylase, implicating improved energy [31] , and enhanced expression in transgenic hearts could metabolism in the protected phenotype.
protect viable cells from apoptosis. We demonstrate reAnother notable observation was repression of structurduced necrosis / infarction in this model [7, 8] , and others al / motility genes ( Table 2 , Fig. 2 ), consistent with cytodemonstrate A AR-mediated inhibition of apoptosis [32] . 1 skeletal and myofibrillar abnormalities post-ischemia [28] . We observe two novel transcriptional changes with It is reasonable to hypothesize some may play a role in A AR overexpression, confirmed by real-time PCR, incon-1 contractile dysfunction and subsequent remodeling. Alsistent with a protected phenotype. First, Ywhag was though proteolysis may play a role [28] , reduced expresdown-regulated post-ischemia, and this was exaggerated by A AR overexpression. The family of 14-3-3 proteins 1 suppress apoptosis [33] , and this is the first report the Ywhag gene may be modulated by ischemia. Secondly, Ddit3 was induced by ischemia in transgenic and wild-type hearts (Fig. 3B) . Regulation of this gene, which induces growth arrest and cell death, has not been reported in heart, although another group recently reported ischemic induction of closely related Gadd45 [34] . Comparable induction of this gene in wild-type and transgenic hearts suggests activation of a cell death program which is insensitive to A AR activation.
1
Induction of several transcription factors was observed in transgenic hearts (DEAD box polypeptides, Msx1, Spop, Sox9). It is tempting to speculate these factors may coordinate expression of groups of genes in transgenic was repressed in wild-type and, to a lesser extent, transin non-ischemic and ischemic transgenic hearts, and ischemic wild-type genic hearts (Fig. 3B ). Due to its structure and expression hearts (n56 in all cases). Expression ratios are shown relative to nonin heart, Fhl2 is implicated as a regulator of cardiac ischemic wild-type hearts (n58) for purposes of comparison. Values are differentiation and phenotype [35] . In terms of protein means6S.E.M. *, P,0.0001 vs. wild-type normoxic; †, P,0.0001 vs. transgenic.
synthesis and modification, we observe repression of mitochondrial and ribosomal genes in wild-type hearts.
repression) determined via microarray analysis of pooled This is reversed in transgenics, with additional ribosomal RNA samples (Fig. 4) [5] , consistent with expression of Adora1 in normoxic underestimate these responses. Although cell-culture might transgenic hearts (Fig. 5) . Paradoxically, ischemia-reperfupermit analysis of homogenous cell populations, the drawsion induced Adora1 in transgenic hearts whereas it was back with this alternate approach is that genotype and moderately down-regulated in wild-type hearts. The A AR phenotype may be substantially altered from the in situ 1 transgene is controlled by the MEF-2 mutated myosin state, metabolic rate is low, and interactions between cell heavy chain (Myhca) promoter. Thus, the differences could types important in inducing injurious or protective rereflect enhanced Myhca expression in post-ischemic transsponses are absent. Analysis of the intact heart does genic hearts. Since Myhca levels are orders of magnitude provide insight into transcriptional control in the intact greater than Adora1, small relative changes in Myhca organ. Subsequent analysis may be necessary to identify expression could result in substantial changes in Adora1 the cellular sites of such responses. expression. However, there is no detectable difference in Myhca expression (Fig. 5) . Importantly, down-regulation of Adora1 in wild-types may adversely effect post-is-4 .5. Conclusions chemic outcome, and receptor density may additionally be reduced by agonist triggered down-regulation. This, cou-
The ischemia-tolerant phenotype with A AR overex-1 pled with repressed transcription, could limit A AR-mepression appears to result from acute activation of A AR 1 1 diated protection. This is supported by a post-ischemic receptors during and following ischemia rather than adapreduction in sensitivity of A AR-mediated bradycardia (see tive changes in phenotype and genotype over the life-span and tissue specificity. Variability in expression data is best overexpression reversed repression of metabolic and struceliminated by replication [14, 36, 37] , and 2-3 replicates are tural / motility genes, enhanced induction of genes controlessential in array studies [14] . Many recent cardiac studies ling gene expression, and altered pro-and anti-apoptotic incorporate limited replicates or report data from single genes, potentially contributing to an anti-apoptotic phenoarrays [3, 22, 23] . Investigators have also utilized 1.8-or type. While the |2000 arrayed genes analysed may 2-fold cut-offs for identifying expression changes [3, 4, 23] .
represent only 10% of the cardiovascular genome [10] , These are not statistically valid, even in duplicated experithese responses provide clues regarding molecular determents [37] , and it is critical to have sufficient replicate minants of ischemic tolerance and the post-ischemic microarray assays to reach reliable conclusions [14] .
phenotype. Similar statistical standards applying to other biological experiments also apply to microarray experiments [36, 37] . We examine expression for genes duplicated on each slide, and report expression data from multiple microarray A cknowledgements experiments (i.e. a minimum of four replicates) and only genes whose expression changes significantly at the P, This work was supported by grants from the National 0.05 level are reported. Importantly, a subset of genes Institutes of Health RO1 grant (HL 59419) and the underwent secondary analysis via quantitative real-time National Heart Foundation of Australia (G 98B 0080 and PCR, validating differential expression (induction and G 99B 0246).
